Skip to main content
Top
Published in: Journal of Translational Medicine 1/2019

Open Access 01-12-2019 | Glucocorticoid | Research

Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess

Authors: Alejandra Tapia-Castillo, Dominic Guanzon, Carlos Palma, Andrew Lai, Eric Barros, Fidel Allende, Andrea Vecchiola, Carlos E. Fardella, Carlos Salomón, Cristian A. Carvajal

Published in: Journal of Translational Medicine | Issue 1/2019

Login to get access

Abstract

Background

The “nonclassic” apparent mineralocorticoid excess (NC-AME) has been identified in approximately 7% of general population. This phenotype is characterized by low plasma renin activity (PRA), high serum cortisol (F) to cortisone (E) ratio, low cortisone, high Fractional Excretion of potassium (FEK) and normal-elevated systolic blood pressure (SBP). An early detection and/or identification of novel biomarkers of this phenotype could avoid the progression or future complications leading to arterial hypertension. Isolation of extracellular vesicles, such as exosomes, in specific biofluids support the identification of tissue-specific RNA and miRNA, which may be useful as novel biomarkers. Our aim was to identify miRNAs within urinary exosomes associated to the NC-AME phenotype.

Methods

We perform a cross-sectional study in a primary care cohort of 127 Chilean subjects. We measured BP, serum cortisol, cortisone, aldosterone, PRA. According to the previous reported, a subgroup of subjects was classified as NC-AME (n = 10). Urinary exosomes were isolated and miRNA cargo was sequenced by Illumina-NextSeq-500.

Results

We found that NC-AME subjects had lower cortisone (p < 0.0001), higher F/E ratio (p < 0.0001), lower serum potassium (p = 0.009) and higher FEK 24 h (p = 0.03) than controls. We found miR-204-5p (fold-change = 0.115; p 0.001) and miR-192-5p (fold-change = 0.246; p 0.03) are both significantly downregulated in NC-AME. miR-192-5p expression was correlated with PRA (r = 0.45; p 0.028) and miR-204-5p expression with SBP (r = − 0.48, p 0.027) and F/E ratio (r = − 0.48; p 0.026).

Conclusions

These findings could support a potential role of these miRNAs as regulators and novel biomarkers of the NC-AME phenotype.
Appendix
Available only for authorised users
Literature
1.
go back to reference Campino C, Carvajal CA, Cornejo J, San Martin B, Olivieri O, Guidi G, Faccini G, Pasini F, Sateler J, Baudrand R, et al. 11beta-Hydroxysteroid dehydrogenase type-2 and type-1 (11beta-HSD2 and 11beta-HSD1) and 5beta-reductase activities in the pathogenia of essential hypertension. Endocrine. 2010;37:106–14.CrossRefPubMed Campino C, Carvajal CA, Cornejo J, San Martin B, Olivieri O, Guidi G, Faccini G, Pasini F, Sateler J, Baudrand R, et al. 11beta-Hydroxysteroid dehydrogenase type-2 and type-1 (11beta-HSD2 and 11beta-HSD1) and 5beta-reductase activities in the pathogenia of essential hypertension. Endocrine. 2010;37:106–14.CrossRefPubMed
2.
go back to reference Myles K, Funder JW. Type I (mineralocorticoid) receptors in the guinea pig. Am J Physiol. 1994;267:E268–72.PubMed Myles K, Funder JW. Type I (mineralocorticoid) receptors in the guinea pig. Am J Physiol. 1994;267:E268–72.PubMed
3.
go back to reference Ferrari P, Lovati E, Frey FJ. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. J Hypertens. 2000;18:241–8.CrossRefPubMed Ferrari P, Lovati E, Frey FJ. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. J Hypertens. 2000;18:241–8.CrossRefPubMed
4.
go back to reference Tapia-Castillo A, Baudrand R, Vaidya A, Campino C, Allende F, Valdivia C, Vecchiola A, Lagos CF, Fuentes CA, Solari S, et al. Clinical, biochemical, and genetic characteristics of “Nonclassic” apparent mineralocorticoid excess syndrome. J Clin Endocrinol Metab. 2019;104:595–603.CrossRefPubMed Tapia-Castillo A, Baudrand R, Vaidya A, Campino C, Allende F, Valdivia C, Vecchiola A, Lagos CF, Fuentes CA, Solari S, et al. Clinical, biochemical, and genetic characteristics of “Nonclassic” apparent mineralocorticoid excess syndrome. J Clin Endocrinol Metab. 2019;104:595–603.CrossRefPubMed
6.
go back to reference Krol J, Busskamp V, Markiewicz I, Stadler MB, Ribi S, Richter J, Duebel J, Bicker S, Fehling HJ, Schubeler D, et al. Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell. 2010;141:618–31.CrossRefPubMed Krol J, Busskamp V, Markiewicz I, Stadler MB, Ribi S, Richter J, Duebel J, Bicker S, Fehling HJ, Schubeler D, et al. Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell. 2010;141:618–31.CrossRefPubMed
8.
go back to reference French KC, Antonyak MA, Cerione RA. Extracellular vesicle docking at the cellular port: extracellular vesicle binding and uptake. Semin Cell Dev Biol. 2017;67:48–55.PubMedPubMedCentralCrossRef French KC, Antonyak MA, Cerione RA. Extracellular vesicle docking at the cellular port: extracellular vesicle binding and uptake. Semin Cell Dev Biol. 2017;67:48–55.PubMedPubMedCentralCrossRef
9.
go back to reference Das S, Halushka MK. Extracellular vesicle microRNA transfer in cardiovascular disease. Cardiovasc Pathol. 2015;24:199–206.CrossRefPubMed Das S, Halushka MK. Extracellular vesicle microRNA transfer in cardiovascular disease. Cardiovasc Pathol. 2015;24:199–206.CrossRefPubMed
10.
go back to reference Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011;1:98–110.PubMed Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011;1:98–110.PubMed
11.
go back to reference Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, Alevizos I. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 2010;16:34–8.CrossRefPubMed Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, Alevizos I. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 2010;16:34–8.CrossRefPubMed
12.
go back to reference Romaine SP, Charchar FJ, Samani NJ, Tomaszewski M. Circulating microRNAs and hypertension–from new insights into blood pressure regulation to biomarkers of cardiovascular risk. Curr Opin Pharmacol. 2016;27:1–7.CrossRefPubMed Romaine SP, Charchar FJ, Samani NJ, Tomaszewski M. Circulating microRNAs and hypertension–from new insights into blood pressure regulation to biomarkers of cardiovascular risk. Curr Opin Pharmacol. 2016;27:1–7.CrossRefPubMed
14.
15.
go back to reference Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526–40.PubMedPubMedCentralCrossRef Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526–40.PubMedPubMedCentralCrossRef
16.
go back to reference Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;71:1269–324. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;71:1269–324.
17.
go back to reference Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904.CrossRefPubMed Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904.CrossRefPubMed
18.
go back to reference Sarker S, Scholz-Romero K, Perez A, Illanes SE, Mitchell MD, Rice GE, Salomon C. Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J Transl Med. 2014;12:204.PubMedPubMedCentralCrossRef Sarker S, Scholz-Romero K, Perez A, Illanes SE, Mitchell MD, Rice GE, Salomon C. Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J Transl Med. 2014;12:204.PubMedPubMedCentralCrossRef
19.
go back to reference Mackowiak SD. Identification of novel and known miRNAs in deep-sequencing data with miRDeep2. Curr Protoc Bioinf. 2011;12:12. Mackowiak SD. Identification of novel and known miRNAs in deep-sequencing data with miRDeep2. Curr Protoc Bioinf. 2011;12:12.
20.
go back to reference Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42:D68–73.CrossRefPubMed Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42:D68–73.CrossRefPubMed
22.
go back to reference Gracia T, Wang X, Su Y, Norgett EE, Williams TL, Moreno P, Micklem G, Karet Frankl FE. Urinary exosomes contain MicroRNAs capable of paracrine modulation of tubular transporters in kidney. Sci Rep. 2017;7:40601.PubMedPubMedCentralCrossRef Gracia T, Wang X, Su Y, Norgett EE, Williams TL, Moreno P, Micklem G, Karet Frankl FE. Urinary exosomes contain MicroRNAs capable of paracrine modulation of tubular transporters in kidney. Sci Rep. 2017;7:40601.PubMedPubMedCentralCrossRef
23.
go back to reference Sun Y, Koo S, White N, Peralta E, Esau C, Dean NM, Perera RJ. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 2004;32:e188.PubMedPubMedCentralCrossRef Sun Y, Koo S, White N, Peralta E, Esau C, Dean NM, Perera RJ. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 2004;32:e188.PubMedPubMedCentralCrossRef
24.
go back to reference Tian Z, Greene AS, Pietrusz JL, Matus IR, Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 2008;18:404–11.PubMedPubMedCentralCrossRef Tian Z, Greene AS, Pietrusz JL, Matus IR, Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 2008;18:404–11.PubMedPubMedCentralCrossRef
25.
go back to reference Mladinov D, Liu Y, Mattson DL, Liang M. MicroRNAs contribute to the maintenance of cell-type-specific physiological characteristics: miR-192 targets Na+/K+-ATPase beta1. Nucleic Acids Res. 2013;41:1273–83.CrossRefPubMed Mladinov D, Liu Y, Mattson DL, Liang M. MicroRNAs contribute to the maintenance of cell-type-specific physiological characteristics: miR-192 targets Na+/K+-ATPase beta1. Nucleic Acids Res. 2013;41:1273–83.CrossRefPubMed
26.
go back to reference Baker MA, Wang F, Liu Y, Kriegel AJ, Geurts AM, Usa K, Xue H, Wang D, Kong Y, Liang M. MiR-192-5p in the kidney protects against the development of hypertension. Hypertension. 2019;73:399–406.PubMedCrossRef Baker MA, Wang F, Liu Y, Kriegel AJ, Geurts AM, Usa K, Xue H, Wang D, Kong Y, Liang M. MiR-192-5p in the kidney protects against the development of hypertension. Hypertension. 2019;73:399–406.PubMedCrossRef
27.
go back to reference Ma X, Lu C, Lv C, Wu C, Wang Q. The expression of miR-192 and its significance in diabetic nephropathy patients with different urine albumin creatinine ratio. J Diabetes Res. 2016;2016:6789402.PubMedPubMedCentral Ma X, Lu C, Lv C, Wu C, Wang Q. The expression of miR-192 and its significance in diabetic nephropathy patients with different urine albumin creatinine ratio. J Diabetes Res. 2016;2016:6789402.PubMedPubMedCentral
28.
go back to reference Nagase M, Fujita T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol. 2013;9:86–98.CrossRefPubMed Nagase M, Fujita T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol. 2013;9:86–98.CrossRefPubMed
29.
go back to reference Loirand G, Pacaud P. Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension. Small GTPases. 2014;5:1–10.CrossRefPubMed Loirand G, Pacaud P. Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension. Small GTPases. 2014;5:1–10.CrossRefPubMed
30.
go back to reference Tapia-Castillo A, Carvajal CA, Campino C, Vecchiola A, Allende F, Solari S, Garcia L, Lavanderos S, Valdivia C, Fuentes C, et al. Polymorphisms in the RAC1 gene are associated with hypertension risk factors in a Chilean pediatric population. Am J Hypertens. 2014;27:299–307.CrossRefPubMed Tapia-Castillo A, Carvajal CA, Campino C, Vecchiola A, Allende F, Solari S, Garcia L, Lavanderos S, Valdivia C, Fuentes C, et al. Polymorphisms in the RAC1 gene are associated with hypertension risk factors in a Chilean pediatric population. Am J Hypertens. 2014;27:299–307.CrossRefPubMed
31.
go back to reference Tapia-Castillo A, Carvajal CA, Campino C, Hill C, Allende F, Vecchiola A, Carrasco C, Bancalari R, Valdivia C, Lagos C, et al. The expression of RAC1 and mineralocorticoid pathway-dependent genes are associated with different responses to salt intake. Am J Hypertens. 2015;28:722–8.CrossRefPubMed Tapia-Castillo A, Carvajal CA, Campino C, Hill C, Allende F, Vecchiola A, Carrasco C, Bancalari R, Valdivia C, Lagos C, et al. The expression of RAC1 and mineralocorticoid pathway-dependent genes are associated with different responses to salt intake. Am J Hypertens. 2015;28:722–8.CrossRefPubMed
32.
go back to reference Kaplan JH. The sodium pump and hypertension: a physiological role for the cardiac glycoside binding site of the Na, K-ATPase. Proc Natl Acad Sci U S A. 2005;102:15723–4.PubMedPubMedCentralCrossRef Kaplan JH. The sodium pump and hypertension: a physiological role for the cardiac glycoside binding site of the Na, K-ATPase. Proc Natl Acad Sci U S A. 2005;102:15723–4.PubMedPubMedCentralCrossRef
33.
go back to reference Dostanic I, Paul RJ, Lorenz JN, Theriault S, Van Huysse JW, Lingrel JB. The alpha2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am J Physiol Heart Circ Physiol. 2005;288:H477–85.CrossRefPubMed Dostanic I, Paul RJ, Lorenz JN, Theriault S, Van Huysse JW, Lingrel JB. The alpha2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am J Physiol Heart Circ Physiol. 2005;288:H477–85.CrossRefPubMed
34.
go back to reference Rudnicki M, Perco P, D’haene B, Leierer J, Heinzel A, Muhlberger I, Schweibert N, Sunzenauer J, Regele H, Kronbichler A, et al. Renal microRNA- and RNA-profiles in progressive chronic kidney disease. Eur J Clin Invest. 2016;46:213–26.CrossRefPubMed Rudnicki M, Perco P, D’haene B, Leierer J, Heinzel A, Muhlberger I, Schweibert N, Sunzenauer J, Regele H, Kronbichler A, et al. Renal microRNA- and RNA-profiles in progressive chronic kidney disease. Eur J Clin Invest. 2016;46:213–26.CrossRefPubMed
35.
go back to reference Wang FE, Zhang C, Maminishkis A, Dong L, Zhi C, Li R, Zhao J, Majerciak V, Gaur AB, Chen S, Miller SS. MicroRNA-204/211 alters epithelial physiology. FASEB J. 2010;24:1552–71.PubMedPubMedCentralCrossRef Wang FE, Zhang C, Maminishkis A, Dong L, Zhi C, Li R, Zhao J, Majerciak V, Gaur AB, Chen S, Miller SS. MicroRNA-204/211 alters epithelial physiology. FASEB J. 2010;24:1552–71.PubMedPubMedCentralCrossRef
36.
go back to reference Lin X, Xu F, Cui RR, Xiong D, Zhong JY, Zhu T, Li F, Wu F, Xie XB, Mao MZ, et al. Arterial calcification is regulated via an miR-204/DNMT3a regulatory circuit both in vitro and in female mice. Endocrinology. 2018;159:2905–16.CrossRefPubMed Lin X, Xu F, Cui RR, Xiong D, Zhong JY, Zhu T, Li F, Wu F, Xie XB, Mao MZ, et al. Arterial calcification is regulated via an miR-204/DNMT3a regulatory circuit both in vitro and in female mice. Endocrinology. 2018;159:2905–16.CrossRefPubMed
37.
go back to reference Friso S, Carvajal CA, Fardella CE, Olivieri O. Epigenetics and arterial hypertension: the challenge of emerging evidence. Transl Res. 2015;165:154–65.CrossRefPubMed Friso S, Carvajal CA, Fardella CE, Olivieri O. Epigenetics and arterial hypertension: the challenge of emerging evidence. Transl Res. 2015;165:154–65.CrossRefPubMed
38.
go back to reference Friso S, Pizzolo F, Choi SW, Guarini P, Castagna A, Ravagnani V, Carletto A, Pattini P, Corrocher R, Olivieri O. Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis. 2008;199:323–7.CrossRefPubMed Friso S, Pizzolo F, Choi SW, Guarini P, Castagna A, Ravagnani V, Carletto A, Pattini P, Corrocher R, Olivieri O. Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis. 2008;199:323–7.CrossRefPubMed
39.
go back to reference Elvira-Matelot E, Zhou XO, Farman N, Beaurain G, Henrion-Caude A, Hadchouel J, Jeunemaitre X. Regulation of WNK1 expression by miR-192 and aldosterone. J Am Soc Nephrol. 2010;21:1724–31.PubMedPubMedCentralCrossRef Elvira-Matelot E, Zhou XO, Farman N, Beaurain G, Henrion-Caude A, Hadchouel J, Jeunemaitre X. Regulation of WNK1 expression by miR-192 and aldosterone. J Am Soc Nephrol. 2010;21:1724–31.PubMedPubMedCentralCrossRef
40.
go back to reference Potus F, Graydon C, Provencher S, Bonnet S. Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series). Pulm Circ. 2014;4:175–84.PubMedPubMedCentralCrossRef Potus F, Graydon C, Provencher S, Bonnet S. Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series). Pulm Circ. 2014;4:175–84.PubMedPubMedCentralCrossRef
41.
go back to reference Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Cote J, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208:535–48.PubMedPubMedCentralCrossRef Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Cote J, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208:535–48.PubMedPubMedCentralCrossRef
42.
go back to reference Yu Z, Zhan X. Xia Li: miR-204 inhibits hypertension by regulating proliferation and apoptosis of vascular smooth muscle cells. Int J Clin Exp Med. 2018;11:8214–22. Yu Z, Zhan X. Xia Li: miR-204 inhibits hypertension by regulating proliferation and apoptosis of vascular smooth muscle cells. Int J Clin Exp Med. 2018;11:8214–22.
Metadata
Title
Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess
Authors
Alejandra Tapia-Castillo
Dominic Guanzon
Carlos Palma
Andrew Lai
Eric Barros
Fidel Allende
Andrea Vecchiola
Carlos E. Fardella
Carlos Salomón
Cristian A. Carvajal
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2019
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-019-02143-8

Other articles of this Issue 1/2019

Journal of Translational Medicine 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.